Fundraising Fox

Luke Evnin

Investor

Managing Director at MPM Capital · Advisor at MPM BioImpact

California

FoundedAmphivena TherapeuticsBlade TherapeuticsFrontier MedicinesMaverick TherapeuticsOncorusPotenza Therapeutics

About

Co-founder of the predecessor company MPM Capital in 1997 and Advisor to the firm. Served as interim CEO of publicly traded Werewolf Therapeutics and co-founded seven MPM portfolio companies including Blade Therapeutics, Harpoon Therapeutics, and Tizona Therapeutics over a 30+ year venture capital career.

LinkedIn ↗X / Twitter ↗

Experience

  1. Vie VenturesCo-Founder; Managing Directorcurrent2025 — presentCambridge, MA
  2. Scleroderma Research FoundationChairpersoncurrent1999 — present
  3. Annulus CellarsProprietorcurrent2020 — presentNapa Valley, CA
  4. Werewolf TherapeuticsChairpersoncurrent2016 — presentCambridge, MA
  5. MPM CapitalCo-Founder; Senior Advisorcurrent1997 — present
  6. Accel PartnersGeneral Partner1990 — 1997

Education

  1. University of California, San FranciscoPhD, BioChemistry1985 — 1990
  2. Princeton UniversityBachelor’s Degree, Molecular Biology

Same school

Also attended University of California, San Francisco48

Douglas CrawfordManaging General Partner at Mission BiocapitalMatt MaurerInvestor at WVV CapitalAlec NielsenFounder & CEO, Asimov & Venture Partner at Pillar VCHarlan LevinePresident of Health Innovation and Policy at Oncology VenturesAdam CottonPrincipal at Novartis Venture FundKatarina PancePrincipal at SR One Capital Management

+ 42 more

Also attended Princeton University488

Fabrice GrindaCo-founder & Managing Partner at FJ LabsAndrewAdvisor at Clear VenturesChristal NgAssociate at Golden Gate VenturesDavid CoatsManaging Director & Co-Founder at Correlation VenturesDan MoreheadFounder & CEO at Pantera CapitalGeoff YangCo-Founder at Redpoint Ventures

+ 482 more

Shared employers

Also worked at Werewolf Therapeutics2

Briggs MorrisonEntrepreneur Partner at MPM BioImpactDerek DiRoccoPartner at RA Capital

Deals · 12

Redona Therapeutics, Inc.Board seat

via MPM Capital · filed Jul 2023 · $76.9M raise

Frontier MedicinesBoard seat

via MPM Capital · filed Jul 2021 · $88.5M raise

Umoja Biopharma, Inc.Board seat

via MPM Capital · filed Jun 2021 · $210M raise

Werewolf TherapeuticsBoard seat

via MPM Capital · filed Aug 2020 · $56.2M raise

Blade TherapeuticsBoard seat

via MPM Capital · filed Oct 2019 · $50M raise

Harpoon TherapeuticsBoard seat

via MPM Capital · filed Nov 2018 · $70M raise

OncorusBoard seat

via MPM Capital · filed Sep 2018 · $61.4M raise

Amphivena TherapeuticsBoard seat

via MPM Capital · filed Jun 2017 · $19.5M raise

Maverick TherapeuticsBoard seat

via MPM Capital · filed Jan 2017 · $56M raise

Trieza TherapeuticsBoard seat

via MPM Capital · filed Dec 2016 · $1 raise

Potenza TherapeuticsBoard seat

via MPM Capital · filed Mar 2016 · $38M raise

Vesuvius PharmaceuticalsBoard seat

via MPM Capital · filed Jan 2015 · $33M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at MPM Capital

Alim Ladha
Senior Associate at MPM Capital
Ansbert Gadicke, M.D.
Chairman at MPM Capital
Ansbert K. Gadicke
Managing Partner at MPM BioImpact
Bard Geesaman
Managing Partner at MPM Capital
Briggs Morrison
Entrepreneur Partner at MPM BioImpact
Chris Bardon, M.D.
Managing Partner at MPM Capital
Dan Hicklin
Managing Partner at MPM Capital
David Kolesky
Principal at MPM Capital